 |
Tricida
Last updated: October 09, 2024
CEO Gerrit Klaerner
USA | Funding: $624M (+)
Website: https://www.tricida.com/
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Website: https://www.tricida.com/
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
